extensive-stage small cell lung cancer
Sep 29, 2026
Roche Announces Positive Interim Results for Sefaxersen in IgA Nephropathy; Lilly’s Olumiant Receives FDA Approval for Pediatric Patients With Severe Alopecia Areata; AbbVie’s JUVMO Receives U.S. FDA Approval for Parkinson’s Disease; Biologics License Application for Ifinatamab Deruxtecan Withdrawn in Extensive-Stage Small Cell Lung Cancer; Mirum Pharmaceuticals Reports Primary Endpoint Success in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Roche Reports Positive Interim Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy Roche announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The trial achieved it...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
